Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx”
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
RecruitingNCT06445088 ↗
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
🏥 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University📍 1 site📅 Started May 2024View details ↗
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
👨⚕️ Yong Yang, Doctor, Fujian Medical University Union Hospital📍 1 site📅 Started Apr 2024View details ↗
RecruitingNCT06698692 ↗
Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
👨⚕️ Xiao L Ge, PHD, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2024View details ↗
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
RecruitingNCT06408584 ↗
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
👨⚕️ Jingao Li, MD, NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital📍 1 site📅 Started Feb 2024View details ↗
RecruitingNCT06307314 ↗
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
👨⚕️ Jian Guan, Ph.D., Nanfang Hospital, Southern Medical University📍 5 sites📅 Started Feb 2024View details ↗
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
RecruitingNCT06321939 ↗
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →